Lanny Kirsch

Physician/Scientist focused on immune repertoire profiling

[VJHemOnc @VJHemOnc]

It feels good to be at meetings again and to be catching up with experts face-to-face 👩‍⚕️👨‍⚕️🙌

We've been talking to Lanny Kirsch (@KirschLanny) about his research and will be sharing it with you soon!

Watch videos here 👉https://t.co/dB4K2n85hK👈

@Myeloma_Society #IMW2021 #MMsm

[Lanny Kirsch @KirschLanny]

Published by @VJHemOnc https://t.co/1bpvyXZ3E7

[Lanny Kirsch @KirschLanny]

@evemariecrane @PebbleChamp Thanks so much for participating Eve. Very much enjoyed chatting with you. Lanny #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane examples of use of NGS in CTCL: https://t.co/XHBVe0mjWT https://t.co/Sv3IGqlPL7 https://t.co/u7Wyk3S9mC #abiochat

[Lanny Kirsch @KirschLanny]

@PebbleChamp #ABioChat PART 2 Also as new therapies emerge may often faster transition to other RX options during patients course

[Lanny Kirsch @KirschLanny]

Good question Greg. May be used as suurogate endpoint measure of drug efficacy leading to faster drug approvals (Part1) #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane I will send three relevant #CTCL publinks #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane #ABioChat But same immunosequencing platform can be used to study immune response to solid tumors #immunotherapy

[Lanny Kirsch @KirschLanny]

@evemariecrane #ABioChat Just to clarify, focus here is on immune receptor sequences not whole genome sequencing (Part 1)

[Lanny Kirsch @KirschLanny]

@PebbleChamp https://t.co/xhvlTzK7hn Here's pubs from @AdaptiveBiotech @ collabs covering use of immunosequencing in Dx #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane more in progress or submitted #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane Yes. Already >30 pubs on MRD https://t.co/xhvlTzK7hn covering multiple indications including plasma in DLBCL #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane @HopkinsMedicine Yep. Measurement of plasma more a surrogate of burden not burden directly, but important #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane @AllisonPJacob @HopkinsMedicine Yep. Measurement of plasma more a surrogate of burden not burden directly, but important

[Lanny Kirsch @KirschLanny]

@CognitionStudio Smart question. Certainly #ALL, #CLL, #Myeloma and being explored in #NHL, #Hodgkins #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane @PebbleChamp Then can track that clone with exquisite sensitivity e.g. 10^-6 #ABioChat

[Lanny Kirsch @KirschLanny]

@evemariecrane @PebbleChamp Yes, but first step is the identification of the sequence in the R-S cells, Need >>signal to background#AbioChat

[Lanny Kirsch @KirschLanny]

One of most significant prognsotic factors is level of early response to Rx #ABioChat

[Lanny Kirsch @KirschLanny]

Level of residual disease can be used to risk stratify patients #ABioChat

[Lanny Kirsch @KirschLanny]

@PebbleChamp Histopath analysis and then sending the path sample with high diseae burden #ABioChat